Launch of generic Tecfidera puts more pressure on Biogen’s pipeline

The introduction of generic competition in the U.S. for MS blockbuster Tecfidera, which accounted for 40% of Biogen’s product revenue last half, puts increased pressure on the remainder of big biotech’s pipeline. 

On Wednesday, Mylan N.V. (NASDAQ:MYL) launched at risk 120 mg and 240 mg dimethyl fumarate delayed release capsules for relapsing forms of multiple sclerosis (MS) following FDA approval...